Thursday, May 17, 2012
J&J drug shows promise in high-risk prostate cancer
(Reuters) - Adding Johnson & Johnson's advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment